Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
PETS's Cash to Debt is ranked higher than
99% of the 351 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.65 vs. PETS: No Debt )
Ranked among companies with meaningful Cash to Debt only.
PETS' s 10-Year Cash to Debt Range
Min: 0.11  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.91
PETS's Equity to Asset is ranked higher than
98% of the 334 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.45 vs. PETS: 0.91 )
Ranked among companies with meaningful Equity to Asset only.
PETS' s 10-Year Equity to Asset Range
Min: 0.17  Med: 0.88 Max: 0.93
Current: 0.91
0.17
0.93
Interest Coverage No Debt
PETS's Interest Coverage is ranked higher than
98% of the 241 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 20.47 vs. PETS: No Debt )
Ranked among companies with meaningful Interest Coverage only.
PETS' s 10-Year Interest Coverage Range
Min: 15.27  Med: 10000.00 Max: 9999.99
Current: No Debt
15.27
9999.99
F-Score: 5
Z-Score: 34.20
M-Score: -3.42
WACC vs ROIC
11.51%
66.36%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 12.04
PETS's Operating margin (%) is ranked higher than
93% of the 352 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.82 vs. PETS: 12.04 )
Ranked among companies with meaningful Operating margin (%) only.
PETS' s 10-Year Operating margin (%) Range
Min: -26.37  Med: 11.95 Max: 17.02
Current: 12.04
-26.37
17.02
Net-margin (%) 7.61
PETS's Net-margin (%) is ranked higher than
91% of the 352 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.74 vs. PETS: 7.61 )
Ranked among companies with meaningful Net-margin (%) only.
PETS' s 10-Year Net-margin (%) Range
Min: -28.25  Med: 7.57 Max: 10.91
Current: 7.61
-28.25
10.91
ROE (%) 24.03
PETS's ROE (%) is ranked higher than
91% of the 343 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 8.22 vs. PETS: 24.03 )
Ranked among companies with meaningful ROE (%) only.
PETS' s 10-Year ROE (%) Range
Min: -236.77  Med: 31.57 Max: 90.8
Current: 24.03
-236.77
90.8
ROA (%) 21.47
PETS's ROA (%) is ranked higher than
98% of the 353 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 3.50 vs. PETS: 21.47 )
Ranked among companies with meaningful ROA (%) only.
PETS' s 10-Year ROA (%) Range
Min: -52.2  Med: 27.82 Max: 47.63
Current: 21.47
-52.2
47.63
ROC (Joel Greenblatt) (%) 113.07
PETS's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 353 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 14.55 vs. PETS: 113.07 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
PETS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -162.9  Med: 123.64 Max: 194.27
Current: 113.07
-162.9
194.27
Revenue Growth (3Y)(%) -0.30
PETS's Revenue Growth (3Y)(%) is ranked lower than
76% of the 293 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 4.10 vs. PETS: -0.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
PETS' s 10-Year Revenue Growth (3Y)(%) Range
Min: -0.3  Med: 16.20 Max: 57.8
Current: -0.3
-0.3
57.8
EBITDA Growth (3Y)(%) 2.00
PETS's EBITDA Growth (3Y)(%) is ranked lower than
55% of the 261 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 3.80 vs. PETS: 2.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
PETS' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -8.7  Med: 24.60 Max: 109.3
Current: 2
-8.7
109.3
EPS Growth (3Y)(%) 2.80
PETS's EPS Growth (3Y)(%) is ranked lower than
56% of the 222 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 4.60 vs. PETS: 2.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
PETS' s 10-Year EPS Growth (3Y)(%) Range
Min: -9  Med: 23.90 Max: 104.1
Current: 2.8
-9
104.1
» PETS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

PETS Guru Trades in Q2 2014

John Buckingham 132,974 sh (+2.20%)
Chuck Royce 351,500 sh (unchged)
Paul Tudor Jones Sold Out
John Hussman Sold Out
John Burbank Sold Out
Jim Simons 1,695,407 sh (-6.70%)
» More
Q3 2014

PETS Guru Trades in Q3 2014

John Buckingham 136,162 sh (+2.40%)
Chuck Royce 351,500 sh (unchged)
Jim Simons 1,589,215 sh (-6.26%)
» More
Q4 2014

PETS Guru Trades in Q4 2014

John Buckingham 137,816 sh (+1.21%)
Jim Simons 1,600,615 sh (+0.72%)
Jim Simons 1,600,615 sh (unchged)
Chuck Royce 351,500 sh (unchged)
» More
Q1 2015

PETS Guru Trades in Q1 2015

James Barrow 212,477 sh (New)
Jim Simons 1,685,032 sh (+5.27%)
John Buckingham 141,371 sh (+2.58%)
Chuck Royce 351,500 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with PETS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 19.53
PETS's P/E(ttm) is ranked higher than
65% of the 279 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 23.70 vs. PETS: 19.53 )
Ranked among companies with meaningful P/E(ttm) only.
PETS' s 10-Year P/E(ttm) Range
Min: 11.25  Med: 16.72 Max: 40.23
Current: 19.53
11.25
40.23
Forward P/E 17.18
PETS's Forward P/E is ranked lower than
57% of the 163 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 15.38 vs. PETS: 17.18 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 19.40
PETS's PE(NRI) is ranked higher than
66% of the 279 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 23.80 vs. PETS: 19.40 )
Ranked among companies with meaningful PE(NRI) only.
PETS' s 10-Year PE(NRI) Range
Min: 11.19  Med: 16.68 Max: 40.4
Current: 19.4
11.19
40.4
P/B 4.60
PETS's P/B is ranked lower than
82% of the 342 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.96 vs. PETS: 4.60 )
Ranked among companies with meaningful P/B only.
PETS' s 10-Year P/B Range
Min: 2.33  Med: 4.48 Max: 13.28
Current: 4.6
2.33
13.28
P/S 1.50
PETS's P/S is ranked lower than
84% of the 352 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.52 vs. PETS: 1.50 )
Ranked among companies with meaningful P/S only.
PETS' s 10-Year P/S Range
Min: 0.84  Med: 1.54 Max: 3.51
Current: 1.5
0.84
3.51
PFCF 11.06
PETS's PFCF is ranked higher than
70% of the 193 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 18.47 vs. PETS: 11.06 )
Ranked among companies with meaningful PFCF only.
PETS' s 10-Year PFCF Range
Min: 7.86  Med: 18.77 Max: 48.76
Current: 11.06
7.86
48.76
POCF 10.85
PETS's POCF is ranked higher than
55% of the 264 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 12.46 vs. PETS: 10.85 )
Ranked among companies with meaningful POCF only.
PETS' s 10-Year POCF Range
Min: 7.64  Med: 17.55 Max: 45.43
Current: 10.85
7.64
45.43
EV-to-EBIT 10.72
PETS's EV-to-EBIT is ranked higher than
75% of the 296 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 15.65 vs. PETS: 10.72 )
Ranked among companies with meaningful EV-to-EBIT only.
PETS' s 10-Year EV-to-EBIT Range
Min: 4.7  Med: 9.50 Max: 25.7
Current: 10.72
4.7
25.7
Shiller P/E 17.65
PETS's Shiller P/E is ranked higher than
68% of the 210 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 23.69 vs. PETS: 17.65 )
Ranked among companies with meaningful Shiller P/E only.
PETS' s 10-Year Shiller P/E Range
Min: 9.84  Med: 20.05 Max: 124.94
Current: 17.65
9.84
124.94
Current Ratio 10.84
PETS's Current Ratio is ranked higher than
98% of the 336 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.21 vs. PETS: 10.84 )
Ranked among companies with meaningful Current Ratio only.
PETS' s 10-Year Current Ratio Range
Min: 0.33  Med: 7.76 Max: 12.2
Current: 10.84
0.33
12.2
Quick Ratio 7.46
PETS's Quick Ratio is ranked higher than
98% of the 336 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.75 vs. PETS: 7.46 )
Ranked among companies with meaningful Quick Ratio only.
PETS' s 10-Year Quick Ratio Range
Min: 0.16  Med: 4.50 Max: 8.1
Current: 7.46
0.16
8.1
Days Inventory 64.75
PETS's Days Inventory is ranked lower than
75% of the 344 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 37.77 vs. PETS: 64.75 )
Ranked among companies with meaningful Days Inventory only.
PETS' s 10-Year Days Inventory Range
Min: 28.38  Med: 60.82 Max: 78.88
Current: 64.75
28.38
78.88
Days Sales Outstanding 3.07
PETS's Days Sales Outstanding is ranked higher than
79% of the 286 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 11.39 vs. PETS: 3.07 )
Ranked among companies with meaningful Days Sales Outstanding only.
PETS' s 10-Year Days Sales Outstanding Range
Min: 2.31  Med: 3.17 Max: 6.05
Current: 3.07
2.31
6.05

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 4.02
PETS's Dividend Yield is ranked higher than
83% of the 446 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.86 vs. PETS: 4.02 )
Ranked among companies with meaningful Dividend Yield only.
PETS' s 10-Year Dividend Yield Range
Min: 0.51  Med: 4.24 Max: 5.85
Current: 4.02
0.51
5.85
Dividend Payout 0.78
PETS's Dividend Payout is ranked lower than
78% of the 277 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 9999.00 vs. PETS: 0.78 )
Ranked among companies with meaningful Dividend Payout only.
PETS' s 10-Year Dividend Payout Range
Min: 0.26  Med: 0.68 Max: 0.78
Current: 0.78
0.26
0.78
Dividend growth (3y) 9.00
PETS's Dividend growth (3y) is ranked higher than
59% of the 155 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 6.90 vs. PETS: 9.00 )
Ranked among companies with meaningful Dividend growth (3y) only.
PETS' s 10-Year Dividend growth (3y) Range
Min: 0  Med: 0.00 Max: 26
Current: 9
0
26
Yield on cost (5-Year) 8.50
PETS's Yield on cost (5-Year) is ranked higher than
94% of the 445 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.16 vs. PETS: 8.50 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
PETS' s 10-Year Yield on cost (5-Year) Range
Min: 1.08  Med: 8.96 Max: 12.34
Current: 8.5
1.08
12.34
Share Buyback Rate 0.90
PETS's Share Buyback Rate is ranked higher than
77% of the 204 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: -0.50 vs. PETS: 0.90 )
Ranked among companies with meaningful Share Buyback Rate only.
PETS' s 10-Year Share Buyback Rate Range
Min: 4.1  Med: 0.90 Max: -48.2
Current: 0.9

Valuation & Return

vs
industry
vs
history
Price/Net Cash 7.92
PETS's Price/Net Cash is ranked higher than
64% of the 28 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 13.69 vs. PETS: 7.92 )
Ranked among companies with meaningful Price/Net Cash only.
PETS' s 10-Year Price/Net Cash Range
Min: 5.34  Med: 11.00 Max: 23.38
Current: 7.92
5.34
23.38
Price/Net Current Asset Value 4.75
PETS's Price/Net Current Asset Value is ranked higher than
58% of the 113 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 6.55 vs. PETS: 4.75 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
PETS' s 10-Year Price/Net Current Asset Value Range
Min: 3.24  Med: 6.60 Max: 40
Current: 4.75
3.24
40
Price/Tangible Book 4.65
PETS's Price/Tangible Book is ranked lower than
74% of the 307 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.26 vs. PETS: 4.65 )
Ranked among companies with meaningful Price/Tangible Book only.
PETS' s 10-Year Price/Tangible Book Range
Min: 3.13  Med: 5.35 Max: 22.5
Current: 4.65
3.13
22.5
Price/Projected FCF 1.27
PETS's Price/Projected FCF is ranked higher than
56% of the 216 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.45 vs. PETS: 1.27 )
Ranked among companies with meaningful Price/Projected FCF only.
PETS' s 10-Year Price/Projected FCF Range
Min: 0.78  Med: 1.34 Max: 6.04
Current: 1.27
0.78
6.04
Price/Median PS Value 0.97
PETS's Price/Median PS Value is ranked higher than
71% of the 341 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.18 vs. PETS: 0.97 )
Ranked among companies with meaningful Price/Median PS Value only.
PETS' s 10-Year Price/Median PS Value Range
Min: 0.33  Med: 0.94 Max: 2.03
Current: 0.97
0.33
2.03
Price/Graham Number 2.03
PETS's Price/Graham Number is ranked lower than
55% of the 246 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.78 vs. PETS: 2.03 )
Ranked among companies with meaningful Price/Graham Number only.
PETS' s 10-Year Price/Graham Number Range
Min: 1.45  Med: 2.06 Max: 5.7
Current: 2.03
1.45
5.7
Earnings Yield (Greenblatt) (%) 9.28
PETS's Earnings Yield (Greenblatt) (%) is ranked higher than
79% of the 351 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 5.50 vs. PETS: 9.28 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
PETS' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 3.9  Med: 10.55 Max: 21.2
Current: 9.28
3.9
21.2
Forward Rate of Return (Yacktman) (%) 3.51
PETS's Forward Rate of Return (Yacktman) (%) is ranked lower than
62% of the 219 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 6.99 vs. PETS: 3.51 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
PETS' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: 0.7  Med: 22.45 Max: 65.7
Current: 3.51
0.7
65.7

Analyst Estimate

Mar16
EPS($) 0.99
EPS without NRI($) 0.99

Business Description

Industry: Retail - Defensive » Pharmaceutical Retailers
Compare:SHDMF, GNC, APNHY, JCOUF, PMC » details
Traded in other countries:PQM.Germany,
PetMed Express Inc was incorporated in the state of Florida in January 1996. The Company is a nationwide pet pharmacy. It markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. It markets its products through national television, online, and direct mail/print advertising campaigns, which aim to increase the recognition of the "1-800-PetMeds" brand name and "PetMeds". It offers a selection of products for dogs and cats. Its current product line contains approximately 3,000 SKUs of the popular pet medications, health products, and supplies. These products include a majority of the brands of medication, such as Frontline Plus, K9 Advantix II, Advantage II, Heartgard Plus, Sentinel, Revolution, and Rimadyl. The Company offers its products through three main sales channels: Internet through its website, telephone contact center through its toll-free number, and direct mail/print through 1-800-PetMeds catalogs, brochures, and postcards. It have designed its website and catalogs to provide a convenient, cost-effective, and informative shopping experience that encourages consumers to purchase products important for a pet's health and quality of life. Its customers are located throughout the United States, with approximately 50% of customers residing in California, Florida, New York, Texas, Pennsylvania, Virginia, North Carolina, and New Jersey. Its primary focus has been on retail customers. Its competitors consist of veterinarians, and online and traditional retailers. Its trademarks include PetMed Express and Design, 1888PetMeds and Design, 1-800-PetMeds and Design, 1-800-PetMeds, and PetMeds. The Company is subject to regulation by the State of Florida and is licensed as a community pharmacy by the Florida Board of Pharmacy.
» More Articles for PETS

Headlines

Articles On GuruFocus.com
10 High-Yielding Small Caps For A Portfolio Return Boost Apr 23 2015 
mfi march 2015 Feb 25 2015 
Bob Olstein Says Forget Amazon, Buy PetSmart, Teradata Jun 13 2014 
PetMed Express Inc. Is Trying Harder to Push Sales Apr 21 2014 
4 Cash Gushing, Undervalued Small Cap Stocks With Zero Debt Apr 08 2014 
4 Biggest Dividend Challengers with Low Debt and Nice Initial Yields Aug 28 2013 
12 Dividend Stocks Sending More Cash to Shareholders Aug 05 2013 
My 3 Favorite Healthcare Dividend Stocks with Highest Float Short Ratio Jun 03 2013 
comment on PETS Mar 02 2013 
comment on PETS Mar 02 2013 

More From Other Websites
PETMED EXPRESS INC Files SEC form 10-Q, Quarterly Report Jul 28 2015
PETMED EXPRESS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jul 27 2015
TrueCar (TRUE) Shares Plunge 35% After Q2 Pre-Announcement - Analyst Blog Jul 24 2015
PETMED EXPRESS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jul 22 2015
PetMed Beats on Q1 Earnings, Misses Sales Estimates - Analyst Blog Jul 21 2015
PETMED EXPRESS INC Files SEC form 8-K, Other Events Jul 20 2015
Edited Transcript of PETS earnings conference call or presentation 20-Jul-15 12:30pm GMT Jul 20 2015
PetMed beats 1Q profit forecasts Jul 20 2015
PetMed beats 1Q profit forecasts Jul 20 2015
PetMed Express D/B/A 1-800-PetMeds Announces Its First Quarter Financial Results and Its $0.18 Per... Jul 20 2015
Q1 2015 Petmed Express Inc Earnings Release - 08:00 am ET Jul 20 2015
Why PetMed Express (PETS) Might Surprise This Earnings Season - Tale of the Tape Jul 17 2015
PETMED EXPRESS INC Files SEC form 8-K, Other Events Jul 15 2015
The Zacks Analyst Blog Highlights: Ctrip.com International, PetMed Express and TripAdvisor - Press... Jul 13 2015
PETMED EXPRESS D/B/A 1-800-PETMEDS TO ANNOUNCE ITS FIRST QUARTER FINANCIAL RESULTS ON JULY 20, 2015 Jul 13 2015
PetMed Express D/B/A 1-800-PetMeds to Announce Its First Quarter Financial Results on July 20, 2015 Jul 13 2015
3 Hot Internet Commerce Stocks for this Earnings Season - Earnings ESP Jul 10 2015
Amazon's New Kindle Paperwhite: Improved Features at $119 - Analyst Blog Jun 22 2015
Google Brings Sidewalk Labs to Make Life in the Cities Easier - Analyst Blog Jun 12 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK